Wissenschaftliche Arbeiten

Doç. Dr. Esra Zeynelgil

53 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Quelle: OpenAlex

  3. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

    The oncologist, 2026

    DOI 10.1093/oncolo/oyag092 PMID 41838398 Frei zugänglicher VolltextQuelle: ORCID

  5. Serum Vitamin D as a Predictor of Immunotherapy Response in Advanced Non-small Cell Lung Cancer

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-4-7 Frei zugänglicher VolltextQuelle: OpenAlex

  6. Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072475 PMID 41976774 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  7. Prognostic Significance of Lung Immune Prognostic Index at Diagnosis in Stage III Non-Small Cell Lung Cancer

    Current oncology (Toronto, Ont.), 2026

    DOI 10.3390/curroncol33010043 PMID 41590363 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  8. Independent factors associated with advanced testicular germ cell tumors: the roles of smoking, lymphovascular invasion, and tumor size

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15598-y PMID 41555284 Frei zugänglicher VolltextQuelle: OpenAlex

  9. Emergency Surgery Independently Predicts Postoperative Recurrence in Patients with Pathologic T3N0M0 Colon Cancer: A Retrospective Single-Center Cohort Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33090526 PMID 42782872 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Association Between Smoking Status and PD-L1 Expression in Metastatic Driver Mutation Negative Non-Small Cell Lung Cancer: A Real-World Cohort Study

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612473 Quelle: OpenAlex

  11. 159eP Prognostic value of the immune checkpoint inhibitor score (IChIS) in palliative immunotherapy-treated non-small cell lung cancer: A real-world study

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.106466 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Real-World Evaluation of the Immune Checkpoint Inhibitor Score (IChIS) in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15197750 PMID 42882209 Frei zugänglicher VolltextQuelle: OpenAlex

  13. Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15218206 Frei zugänglicher VolltextQuelle: ORCID

  14. Long-Term Outcomes and Prognostic Factors in Metastatic ALK-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center

    Cancers, 2026

    DOI 10.3390/cancers18172772 PMID 42738294 Frei zugänglicher VolltextQuelle: ORCID

  15. Hormon Pozitif Metastatik Meme Kanseri Tedavisi

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852.c2779 Quelle: ORCID

  16. Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma

    Seminars in Thoracic and Cardiovascular Surgery, 2026

    DOI 10.1053/j.semtcvs.2025.08.007 PMID 40975455 Quelle: ORCID

  17. Prognostic Value of STAS, Lymph Node Metastasis, and VPI in NSCLC ≤ 4 cm Treated with Lobectomy

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm15010233 PMID 41517482 Frei zugänglicher VolltextQuelle: OpenAlex

  18. BMI and PNI as predictors of treatment completion and survival in locally advanced HNSCC receiving sequential chemoradiotherapy

    BMC cancer, 2025

    DOI 10.1186/s12885-025-15240-3 PMID 41398663 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  19. Prognostic Value of Inflammatory Markers, CA 19-9, MELD Score, and ECOG in Stage 4 Gastric Cancer with Liver Metastases

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-5-4 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  20. Prognostic Significance of Dynamic Inflammatory Indices in Head and Neck Cancer During Induction Chemotherapy

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-11-3 Frei zugänglicher VolltextQuelle: OpenAlex

  21. Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab

    Journal of inflammation research, 2025

    DOI 10.2147/jir.s541842 PMID 41209385 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  22. Prognostic Factors and Treatment Outcomes in Pulmonary Adenoid Cystic Carcinoma

    Eurasian Journal of Medical Investigation, 2025

    DOI 10.14744/ejmi.2025.45789 Quelle: OpenAlex

  23. The effect of sarcopenia on survival in patients with metastatic colon cancer

    Oncology in Clinical Practice, 2025

    DOI 10.5603/ocp.104294 Frei zugänglicher VolltextQuelle: OpenAlex

  24. Treatment Outcomes and Prognostic Factors Affecting Survival in Thymic Carcinoma

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-11-5 Frei zugänglicher VolltextQuelle: OpenAlex

  25. Gastrointestinal sistem maligniteli hastalarda demir eksikliği ve kronik hastalık anemisi ayırıcı tanısında soluble transferrin reseptör düzeylerinin yeri

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1637448 Frei zugänglicher VolltextQuelle: ORCID

  26. Dynamic Alteration of HALP Score as a Predictor in Patients with Receiving Immunotherapy for Advanced Non-Small Cell Lung Cancer

    Medicina, 2025

    DOI 10.3390/medicina61060989 PMID 40572677 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  27. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

    Medicina, 2025

    DOI 10.3390/medicina61010144 PMID 39859125 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  28. Prognostic value of hemoglobin-to-red cell distribution width ratio and inflammation markers in colorectal cancer

    World Journal of Gastrointestinal Oncology, 2025

    DOI 10.4251/wjgo.v17.i6.106603 PMID 40547180 Frei zugänglicher VolltextQuelle: ORCID

  29. Challenging the age barrier: comparative outcomes in octogenarian and non-octogenarian colorectal cancer patients

    BMC Geriatrics, 2025

    DOI 10.1186/s12877-025-06722-x PMID 41388513 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-18 Frei zugänglicher VolltextQuelle: OpenAlex

  31. The effect of tumor laterality on prognosis in metastatic renal cell carcinoma

    Adıyaman Üniversitesi Sağlık Bilimleri Dergisi, 2024

    DOI 10.30569/adiyamansaglik.1446010 Frei zugänglicher VolltextQuelle: ORCID

  32. Can platelet distribution width lymphocyte ratio be a novel biomarker for predicting survival in metastatic renal cell cancer?

    Turkish Journal of Clinics and Laboratory, 2024

    DOI 10.18663/tjcl.1460375 Frei zugänglicher VolltextQuelle: ORCID

  33. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma

    Clinical Lung Cancer, 2024

    DOI 10.1016/j.clc.2024.05.004 Quelle: ORCID

  34. Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinoma

    Journal of Clinical Oncology, 2024

    DOI 10.1016/j.cllc.2024.05.004 PMID 38871540 5 Zitationen (OpenAlex) Quelle: ORCID

  35. Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinoma.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e20609 1 Zitation (OpenAlex) Quelle: OpenAlex

  36. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Sunitinib Versus Pazopanib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate and Poor-Risk Characteristics: Real-World, a Single-Center

    Journal of Cancer Treatment and Research, 2023

    DOI 10.11648/j.jctr.20231101.11 Frei zugänglicher VolltextQuelle: OpenAlex

  38. Assessment Of Serum Cyanocobalamin Level And Importance In Patients With Hematological Malignancies

    Turkish Journal of Clinics and Laboratory, 2023

    DOI 10.18663/tjcl.1225685 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  39. The Effect of Sarcopenia on Survival in Patients with Metastatic Colon Cancer

    Research Square, 2023

    DOI 10.21203/rs.3.rs-2512818/v1 Frei zugänglicher VolltextQuelle: ORCID

  40. Nadir Tümörler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.2239 1 Zitation (OpenAlex) Quelle: ORCID

  41. Sarkomlar ve Cilt Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1097 Frei zugänglicher VolltextQuelle: OpenAlex

  42. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Frei zugänglicher VolltextQuelle: OpenAlex

  43. Malign Peritoneal Mezotelyoma

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.2239.c17284 Quelle: OpenAlex

  44. Efficacy and Tolerability of Current Treatments for Hormone-Refractory Prostate Cancer Patients with Visceral Metastases

    Future Oncology, 2021

    DOI 10.2217/fon-2020-1032 PMID 33631986 Quelle: OpenAlex

  45. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-021-03748-7 PMID 34331582 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  46. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

    Future oncology (London, England), 2021

    DOI 10.2217/fon-2021-0597 PMID 34342517 28 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

  47. The prognostic value of the red cell distribution width to platelet count ratio in patients with breast cancer,Meme kanserli hastalarda kırmızı küre dağılım genişliğinin trombosit sayısına oranının prognostik değeri

    Turkiye Klinikleri Journal of Medical Sciences, 2020

    DOI 10.5336/medsci.2019-71722 Frei zugänglicher VolltextQuelle: ORCID

  48. Küçük hücreli akciğer kanserinde (KHAK) prognostik parametre olarak nötrofil, lenfosit, LDH ve NLO değerleri ile NLO’nun sağkalıma etkisi

    2020

    Quelle: OpenAlex

  49. The effect of neutrophil, lymphocyte, LDH and NLO on overall survival as a prognostic parameter in small cell lung cancer (SCLC)

    Uluslararası Modern Sağlık Bilimleri Dergisi, 2020

    Quelle: ORCID

  50. A new prognostic index in patients with hormone receptor-positive and HER2-negative breast cancer,Nowy wskaźnik prognostyczny u pacjentek z rakiem piersi i ekspresja receptorów hormonalnych oraz brakiem ekspresji HER2

    Current Gynecologic Oncology, 2019

    DOI 10.15557/cgo.2019.0020 Frei zugänglicher VolltextQuelle: ORCID